2 June 2021 - Nearly two decades ago, in Washington DC, a group of consultants, lobbyists, lawyers and pharmaceutical industry representatives met in a big boardroom fronting Pennsylvania Avenue to hammer out a strategy to undermine PHARMAC in New Zealand.
The most immediate problem was not that the organisation was performing badly, but rather that it was doing too well.